Cannonsburg, Pa.-based Mylan recalled about 81,000 EpiPens after two separate reports of the device failing to administer epinephrine during emergency situations, reports Reuters.
Here are three things to know.
1. The recall applies to EpiPens distributed in Australia, New Zealand, Europe and Japan.
2. Both individuals who tried to use the faulty EpiPens sought treatment through the use of an alternate EpiPen, Mylan said Wednesday in a statement.
3. Mylan said it is working with regulatory authorities to notify them of the recall, according to the report.
More articles on supply chain:
Trump meets with Congressional Black Caucus, promises lower drug costs
Study: Surgeon scorecards reduce supply cost without affecting outcomes
FDA grants tentative approval to Mylan's HIV/AIDS drug: 3 things to know